These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35614917)

  • 1. Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study.
    Weber MS; Buttmann M; Meuth SG; Dirks P; Muros-Le Rouzic E; Eggebrecht JC; Hieke-Schulz S; Leemhuis J; Ziemssen T
    Front Neurol; 2022; 13():863105. PubMed ID: 35614917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
    Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
    BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
    Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
    Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
    Derfuss T; Bermel R; Lin CJ; Hauser SL; Kappos L; Vollmer T; Comi G; Giovannoni G; Hartung HP; Weber MS; Wang J; Jessop N; Chognot C; Craveiro L; Bar-Or A
    Ther Adv Neurol Disord; 2024; 17():17562864241277736. PubMed ID: 39399100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain.
    Sempere AP; Berenguer-Ruiz L; Borrego-Soriano I; Burgos-San Jose A; Concepcion-Aramendia L; Volar L; Aragones M; Palazón-Bru A
    Front Neurol; 2020; 11():592304. PubMed ID: 33519676
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Hauser SL; Kappos L; Montalban X; Craveiro L; Chognot C; Hughes R; Koendgen H; Pasquarelli N; Pradhan A; Prajapati K; Wolinsky JS
    Neurology; 2021 Oct; 97(16):e1546-e1559. PubMed ID: 34475123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Nov; 79():104941. PubMed ID: 37633033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
    Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
    Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
    Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
    EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.
    Martins P; Vandewalle B; Félix J; Capela CM; Cerqueira JJ; Salgado AV; Ferreira DG; Monteiro I
    Pharmacoecon Open; 2023 Mar; 7(2):229-241. PubMed ID: 36454397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study.
    Lanzillo R; Carotenuto A; Signoriello E; Iodice R; Miele G; Bisecco A; Maniscalco GT; Sinisi L; Romano F; Di Gregorio M; Lavorgna L; Trojsi F; Moccia M; Fratta M; Capasso N; Dubbioso R; Petracca M; Spiezia AL; Gallo A; Petruzzo M; De Angelis M; Bonavita S; Lus G; Tedeschi G; Brescia Morra V
    J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
    Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
    Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers.
    Diem L; Ovchinnikov A; Friedli C; Hammer H; Kamber N; Chan A; Salmen A; Findling O; Hoepner R
    Mult Scler Relat Disord; 2024 Jun; 86():105570. PubMed ID: 38604001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review.
    Petrie JL; Smith CA; Fountain D; Machnicki G
    Neurol Ther; 2024 Dec; 13(6):1597-1605. PubMed ID: 39425889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.